A tooth-mounted sensor, a glucose monitor built into a smartphone case, plus 3 more new “gee whiz” devices that could transform diabetes care.
DASH4D Diet Reduces BP by 4.6 mm Hg in Adults with T2D on Maximal Antihypertensive Therapy
For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
High Discontinuation Rates of GLP-1 RA-Based Drugs Linked to Weight Loss Far Below Phase 3 Clinical Trials
High discontinuation rates as well as lower maintenance dosages of semaglutide and tirzepatide were among the independent predictors of lower real-world weight loss.
Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.
ASCO 2025: GLP-1 Receptor Agonists Linked to Modest Reduction in Obesity-Related Cancer Risk
GLP-1 receptor agonists showed promise in lowering obesity-related cancer risks in adults with type 2 diabetes, particularly colorectal cancer.
Investigational GPR119 Agonist Shows Dual Hepatoprotective and Glycemic Benefits in MASH Patients
EASL 2025. DA-1241 significantly reduced plasma ALT levels, improved systemic inflammatory and fibrosis biomarkers, according to drug developer MetaVia.